US Department of Health and Human Services, Food and Drug Administration & Center for Drug Evaluation and Research (CDER). Obesity and overweight: developing drugs and biological products for weight reduction guidance for industry. FDA https://www.fda.gov/media/71252/download (2025).
Tinsley, G. M. & Heymsfield, S. B. Fundamental body composition principles provide context for fat-free and skeletal muscle loss with GLP-1 RA treatments. J. Endocr. Soc. 8, bvae164 (2024).
Langer, H. T. et al. Weight loss with GLP-1 medicines does not result in a disproportionate loss of muscle mass or function in obese mice and humans. Cell Rep. Med. 7, 102665 (2026).
Heymsfield, S. B. et al. Bimagrumab plus semaglutide alone or in combination for the treatment of obesity: a randomized phase 2 trial. Nat. Med. 32, 869–882 (2026).
Kochlik, B. et al. Frailty is characterized by biomarker patterns reflecting inflammation or muscle catabolism in multi-morbid patients. J. Cachexia Sarcopenia Muscle 14, 157–166 (2023).
Crow, R. S. et al. Reported weight change in older adults and presence of frailty. J. Frailty Aging 9, 74–81 (2020).
Winter, J. E., MacInnis, R. J., Wattanapenpaiboon, N. & Nowson, C. A. BMI and all-cause mortality in older adults: a meta-analysis. Am. J. Clin. Nutr. 99, 875–890 (2014).
Prokopidis, K. Glucagon-like peptide-1 receptor agonists and muscle strength changes in older adults: risks beyond muscle mass reductions. Br. J. Pharmacol. https://doi.org/10.1111/bph.70355 (2026).
Suetta, C. et al. Ageing is associated with diminished muscle re-growth and myogenic precursor cell expansion early after immobility-induced atrophy in human skeletal muscle. J. Physiol. 591, 3789–3804 (2013).
Goodpaster, B. H. et al. The loss of skeletal muscle strength, mass, and quality in older adults: the health, aging and body composition study. J. Gerontol. A Biol. Sci. Med. Sci. 61, 1059–1064 (2006).
West, S. et al. Weight regain after cessation of medication for weight management: systematic review and meta-analysis. BMJ 392, e085304 (2026).